Zwitterionic reagents for labeling, cross-linking and improving the performance of chemiluminescent immunoassays
作者:Anand Natrajan、David Sharpe、David Wen
DOI:10.1039/c2ob06807a
日期:——
Improving reagent performance in immunoassays both to enhance assay sensitivity and to minimize interference are ongoing challenges in clinical diagnostics. We describe herein the syntheses of a new class of hydrophilic reagents containing sulfobetaine zwitterions and their applications. These zwitterionic reagents are potentially useful for improving the properties of immunoassay reagents. We demonstrate
This invention relates to novel 4-trimethylammoniobutyrates of the formula
wherein A
1
, R
1
, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments.
This invention relates to novel 4-dimethylaminobutyric acid derivatives of the formula
wherein A
1
, A
2
, R
1
, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments in methods for the treatment of diseases modulated by CPT2 inhibitors.
Labeling agents for mass spectrometry comprising tertiary amines
申请人:Hamon Christian
公开号:US20070023628A1
公开(公告)日:2007-02-01
Provided is a method for characterising a molecule by mass spectrometry, which molecule comprises one or more free amino groups, which method comprises: (a) reacting one or more free amino groups in the molecule with a mass tag reagent comprising a reactive functionality capable of reacting with an amino group, and a tertiary amino group linked to the reactive functionality; and (b) characterising the molecule by mass spectrometry.
This invention relates to novel 4-dimethylaminobutyric acid derivatives of the formula
wherein A1, A2, R1, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments in methods for the treatment of diseases modulated by CPT2 inhibitors.